Qiagen stock holds steady as Berenberg reiterates Neutral rating
Published on 09/11/2026 at 14:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Qiagen N.V. stock (ISIN NL0012169213) traded around 42.13 dollars on the New York Stock Exchange as of September 10, 2026, after slipping 0.87 percent from the prior close, keeping the life sciences group in a tight range ahead of its next earnings release on November 10, 2026.
Berenberg reiterates Neutral view
According to MarketScreener on September 11, 2026, analyst Sam England at Berenberg reaffirmed a Neutral rating on Qiagen, keeping the price target unchanged at 40 euros, which sets a benchmark slightly below recent US trading levels when converted into dollars based on prevailing exchange rates.
As MarketScreener Italy reported on September 11, 2026, the note highlights that the target price of 40 euros is unchanged, while the last closing price of Qiagen’s American depositary shares stood at 42.13 dollars on the New York Stock Exchange, implying a modest downside versus the analyst’s euro-denominated valuation.
Leadership change and valuation debate
As Kalkine Media reported, Jonathan M. Pratt formally assumed the role of chief executive officer at Qiagen N.V. on September 1, 2026, succeeding Thierry Bernard, who stepped down from the Managing Board, a transition that positions Pratt to steer the company through its next phase of growth and portfolio execution.
Qiagen’s positioning in diagnostics and life sciences tools has prompted ongoing valuation discussions, with Kalkine Media on September 10, 2026, describing the shares as entering a particularly interesting phase as investors weigh growth opportunities in molecular testing against macroeconomic and sector-specific risks.
Recent price performance and trading range
Finance portal data summarized in recent coverage show that Qiagen’s American depositary shares closed at 42.13 dollars on the New York Stock Exchange on September 10, 2026, down 0.87 percent on the day, after previously ending the September 9, 2026 session around 42.50 dollars with a gain of 0.28 percent over the prior close, indicating only modest short-term volatility in the stock.
Based on the same price context, Qiagen stock has moved roughly 3.9 percent lower over the past five trading days leading up to September 11, 2026, reflecting a pullback from recent levels that still leaves the shares within their established range and close to the consolidated market capitalization band around the mid single-digit billion dollar mark.
Next earnings date provides a key checkpoint
According to data relayed from CNN markets and referenced in market commentary published on September 10, 2026, Qiagen’s next scheduled quarterly earnings release is set for November 10, 2026, which will give investors a fresh look at revenue trends, earnings development and margin dynamics for the most recent reporting period.
The upcoming earnings report is expected to update the picture that previously showed Qiagen delivering above-market growth in core molecular diagnostics and sample preparation, while managing currency headwinds and competitive pressures in its life sciences tools portfolio, making the November 10, 2026 date an important milestone for holders of Qiagen stock.
Stock price and market snapshot
As of the last completed US trading day before publication, Qiagen stock closed at 42.13 dollars on the New York Stock Exchange on September 10, 2026, representing a daily decline of 0.87 percent compared with the prior close, with trading volume in line with typical levels for the ticker QGEN and an indicative market capitalization in the upper single-digit billion dollar range in US dollars.
Qiagen stock at a glance
- Company: Qiagen N.V.
- ISIN: NL0012169213
- Ticker: QGEN
- Trading venue: New York Stock Exchange (ADR)
- Price (as of September 10, 2026, 4:00): 42.13 USD
- Market capitalization: approximately 8.7 billion USD (as of September 10, 2026)
- Sector / Industry: Health Care / Life Sciences Tools and Services
- Index membership: DAX 40
- Next earnings date: November 10, 2026
